"uuid:ID","name","bcCategories","studyEstimands","studyInvestigationalInterventions","documentVersion","studyDesignRationale","id","label","description"
"5c9d0b44-cf25-4f27-b204-78a3366374ed","Study Design 1","[]","[]","[]","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","","The main design for the study"
